



Press  
release

Montpellier, April 16<sup>th</sup> 2020 – 08h30 AM CEST

## New version of the COVID-19 protocol

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and designer of Myrian, continues its involvement in the fight against COVID-19 and announces the availability on Friday April 17<sup>th</sup>, 2020 of a second version of its scanner reading protocol dedicated to the epidemic.

### A new version authorized by the FDA and in the process of CE marking

A new milestone has been reached for this new application, which is authorized by the FDA in the United-States, and should receive its CE marking for Europe in the next few days. These authorizations place the new version of the protocol in the category of medical devices, which can therefore be used in an even broader clinical context, from screening to diagnosis and large-scale therapeutic trials to find an effective treatment against the virus.

### An application benefiting from numerous high-level collaborations

With more than 280 licenses requests since the start of the operation, the company has benefited from numerous positive feedbacks and requests for evolution and collaboration on this new protocol, in France and abroad. Thanks to the flexibility of the Myrian platform and the Myrian Studio approach, the new dedicated COVID-19 protocol has been developed in a few weeks and the improvements taken into account in a few days demonstrate the company's ability to be extremely agile when faced with new needs.

Nicolas Reymond, CEO of Intrasense, explains: "We are proud of what has been accomplished in such a short time by our teams and I would like to warmly thank all the radiologists who helped us build this new version, especially in France and in Italy. Without them it would not have been possible. "



### An even more precise and intuitive solution

Many new features have been incorporated into this second version of the solution.

It is now possible to get a separate volume for the right and left lungs. Thresholding has also been improved and becomes even more precise, allowing allowing after calculation of the pulmonary volume to threshold and define the percentage after a lung segmentation, to threshold and define the percentage of “frosted glass” type lesions and “condensation” type lesions. The protocol therefore provides clinicians with an overall lung volume, the overall volume of lesions as well as the details by type (frosted glass, condensation, etc.), making it possible to precisely quantify lung damage and automatically generate a complete report according to the recommendations of learned societies. of radiology.

Pioneer in the development of a specific COVID-19 solution for scanner imaging, the company provides unique tools at a worldwide level for their precision in quantifying and monitoring pathology.

Nicolas Reymond indicates: "Our teams are fully mobilized on the subject in order to help our users, on the front line in this fight against the epidemic, to benefit from the best tools for patient care. Our mission is to support them as well as possible during this period, by making this new version of our solution available for free and by continuing to work with them hand in hand. Thank you to them for their dedication to save lives. "



### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: [www.intrasense.fr](http://www.intrasense.fr)

### Contacts

Intrasense  
Jérémy Peyron  
Marketing & Communication manager  
1231 avenue du Mondial 98, 34000  
Montpellier, FRANCE  
Tel: +334 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor Relations and Financial  
Communication  
Roxane Gbedigro  
Paris, FRANCE  
Tel: +331 44 71 20 43  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

